Business Standard

Biogen agrees to pay $900 mn to settle doctor kickback allegations

Biogen has agreed to pay $900 mn to resolve allegations that it violated federal law by paying kickbacks to doctors to persuade them to prescribe its multiple sclerosis drugs

Biogen

Photo: Reuters

AP Boston
Biogen has agreed to pay USD 900 million to resolve allegations that it violated federal law by paying kickbacks to doctors to persuade them to prescribe its multiple sclerosis drugs, federal prosecutors said.
The agreement announced on Monday settles a whistleblower lawsuit brought by former Biogen employee Michael Bawduniak, according to a statement from the office of US attorney for Massachusetts, Rachael Rollins.
Under the terms of the settlement, Biogen will pay more than USD 843 million to the federal government and more than USD 56 million to 15 states for overbilling Medicare and Medicaid insurance programs.
Bawduniak will receive a portion of the federal recovery.
The Cambridge, Massachusetts-based pharmaceutical company in a statement said it settled so it can focus on our patients and strategic priorities" and said the settlement does not include an admission of liability.
Biogen believes its intent and conduct was at all times lawful and appropriate and Biogen denies all allegations raised in this case," the company's statement said.
The lawsuit alleged that from January 2009 through March 2014, Biogen paid physicians speaking fees, consulting fees and brought them meals that were actually kickbacks, to get them to prescribe Avonex, Tysabri and Tecfidera in violation of the Anti-Kickback Statute.
We thank Mr. Bawduniak for uncovering this behaviour and bringing it to light, Rollins said. This matter is an important example of the vital role that whistleblowers and their attorneys can play in protecting our nation's public health care programs.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Sep 27 2022 | 7:30 PM IST

Explore News